The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. by Yip, B, Steeples, V, Repapi, E, Armstrong, R, Llorian, M, Roy, S, Shaw, J, Dolatshad, H, Taylor, S, Verma, A, Bartenstein, M, Vyas, P, Cross, N, Malcovati, L, Cazzola, M, Hellström-Lindberg, E, Ogawa, S, Smith, C, Pellagatti, A, Boultwood, J

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells by Shastri, A, Choudhary, G, Teixeira, M, Gordon-Mitchell, S, Ramachandra, N, Bernard, L, Bhattacharyya, S, Lopez, R, Pradhan, K, Giricz, O, Ravipati, G, Wong, L, Cole, S, Bhagat, T, Feld, J, Dhar, Y, Bartenstein, M, Thiruthuvanathan, V, Wickrema, A, Ye, B, Frank, D, Pellagatti, A, Boultwood, J, Zhou, T, Kim, Y, Macleod, A, Epling-Burnette, P, Ye, M, McCoon, P, Woessner, R, Steidl, U, Will, B, Verma, A

Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome by Bhagat, T, Chen, S, Bartenstein, M, Barlowe, TS, von Ahrens, D, Choudhary, GS, Tivnan, P, Amin, E, Marcondes, AM, Sanders, MA, Hoogenboezem, RM, Kambhampati, S, Ramachandra, N, Mantzaris, I, Sukrithan, V, Laurence, R, Lopez, R, Bhagat, P, Giricz, O, Sohal, D, Wickrema, A, Yeung, CC, Gritsman, K, Aplan, PD, Hochedlinger, K, Yu, Y, Pradhan, K, Zhang, J, Greally, J, Mukherjee, S, Pellagatti, A, Boultwood, J, Will, B, Steidl, U, Raaijmakers, MH, Deeg, HJ, Kharas, MG, Verma, A